CIAM
CRBP icon

Caitong International Asset Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Caitong International Asset Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-511
Closed -$2.71K – 2084
2025
Q1 		$2.71K Buy
511
+438
+600% +$3.87K ﹤0.01% 1228
2024
Q4 		$861 Buy
+73
New +$1.22K ﹤0.01% 1363

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return

Caitong International Asset Management's CRBP Position: Q2 2025 in Review

Caitong International Asset Management sold out of Corbus Pharmaceuticals (CRBP) in Q2 2025, closing a stake of 511 shares — an estimated $2.71K sold.

Caitong International Asset Management first reported a position in CRBP in Q4 2024 and held it in 2 quarters. The position peaked at $2.71K in Q1 2025. 80 funds tracked by Wall St. Rank hold CRBP as of Q2 2025.

  • Caitong International Asset Management reported no remaining Corbus Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Caitong International Asset Management sold 511 Corbus Pharmaceuticals shares in Q2 2025, an estimated $2.71K.
  • Caitong International Asset Management first reported a position in Corbus Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Caitong International Asset Management's Corbus Pharmaceuticals position peaked at $2.71K in Q1 2025.
  • 80 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2025.

Based on Caitong International Asset Management's 13F filing for Q2 2025, filed 31 Jul 2025.